Literature DB >> 7523271

Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients.

Y Kanazawa1, N Hayashi, E Mita, T Li, H Hagiwara, A Kasahara, H Fusamoto, T Kamada.   

Abstract

The quasispecies nature of hepatitis C virus genome distribution is most evident in hypervariable regions of the putative envelope 2 domain. Eight patients with chronic hepatitis C treated with interferon-alpha were studied as to heterogeneity of the hypervariable regions to clarify the implications of quasispecies. More than 10 recombinant clones generated from polymerase chain reaction-amplified products of the hypervariable regions were sequenced. The sets of clones derived from long-term responders before interferon therapy showed a significantly lower (p < 0.05) degree of sequence complexity of the hypervariable region 1 quasispecies than those from short-term ones or non-responders. The values of nucleotide diversity (the average number of nucleotide differences per site between two randomly chosen sequences) in hypervariable region 1 before interferon therapy were also significantly lower (p < 0.05) for long-term responders (mean, 2.31 x 10(-2)). In some cases, nucleotide diversity decreased remarkably during interferon therapy, whereas the values remained unchanged in other cases. In one interesting case, a short-term response was first noted with the nucleotide diversity decreasing from 13.98 x 10(-2) to 0.21 x 10(-2); namely, the diversity of the quasispecies was significantly reduced, and then a long-term response was observed after an additional course of interferon therapy. Thus, the degree of quasispecies' complexity and diversity of hypervariable region 1 was closely correlated with the responsiveness to interferon therapy in chronic hepatitis C patients, and thus may have some influence on interferon efficacy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7523271

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  24 in total

1.  Clinical guidelines on the management of hepatitis C.

Authors:  J C Booth; J O'Grady; J Neuberger
Journal:  Gut       Date:  2001-07       Impact factor: 23.059

2.  Combined therapy with interferon and ribavirin in chronic hepatitis C does not affect serum quasispecies diversity.

Authors:  S Sookoian; G Castaño; B Frider; J Cello; R Campos; D Flichman
Journal:  Dig Dis Sci       Date:  2001-05       Impact factor: 3.199

3.  Quasispecies as predictive response factors for antiviral treatment in patients with chronic hepatitis C.

Authors:  Javier Salmerón; Paloma Muñoz De Rueda; Angela Ruiz-Extremera; Jorge Casado; Carlos Huertas; Maria Del Carmen Bernal; Luis Rodríguez; Angel Palacios
Journal:  Dig Dis Sci       Date:  2006-05       Impact factor: 3.199

Review 4.  Viral determinants of resistance to treatment in patients with hepatitis C.

Authors:  Anette Wohnsland; Wolf Peter Hofmann; Christoph Sarrazin
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

Review 5.  [Therapy of hepatitis C].

Authors:  D M Alscher; J C Bode
Journal:  Med Klin (Munich)       Date:  1997-03-15

Review 6.  The quasispecies of hepatitis C virus and the host immune response.

Authors:  P Farci; J Bukh; R H Purcell
Journal:  Springer Semin Immunopathol       Date:  1997

7.  Predictors of response to interferon therapy.

Authors:  G Saracco; M Rizzetto
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

Review 8.  Hepatitis C virus: molecular biology and genetic variability.

Authors:  C Bréchot
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

9.  Structural analysis of hepatitis C RNA genome using DNA microarrays.

Authors:  María Martell; Carlos Briones; Aránzazu de Vicente; María Piron; Juan I Esteban; Rafael Esteban; Jaime Guardia; Jordi Gómez
Journal:  Nucleic Acids Res       Date:  2004-06-24       Impact factor: 16.971

10.  Quasispecies of genotype 4 of hepatitis C virus genomes in Saudi patients managed with interferon alfa and ribavirin therapy.

Authors:  Ahmed A Al-Qahtani; George Kessie; Damian Dela Cruz; Faleh Z Al-Faleh; Mohammed N Al-Ahdal
Journal:  Ann Saudi Med       Date:  2010 Mar-Apr       Impact factor: 1.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.